
Phase I trial shows Parkinson’s peptide crosses blood-brain barrier
Teitur Trophics has announced successful results from its Phase I clinical trial of lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD). The data show TT-P34 crosses the blood-brain barrier, leading to robust, dose-dependent exposure within the brain and central nervous system (CNS). Read More
